Amedisys Reports Third Quarter 2024 Financial Results
Amedisys (NASDAQ: AMED) reported its Q3 2024 financial results with net service revenue increasing to $587.7 million, up from $556.2 million in 2023. Net income was $16.9 million ($0.51 per diluted share), compared to $26.0 million ($0.79 per share) in 2023, including merger-related expenses of $16.7 million. For the nine-month period, revenue grew to $1,750.3 million from $1,665.6 million, with net income of $63.6 million compared to a net loss of $29.1 million in 2023. Adjusted EBITDA for Q3 2024 was $58.1 million, slightly up from $57.9 million in 2023.
Amedisys (NASDAQ: AMED) ha riportato i risultati finanziari del terzo trimestre del 2024, con ricavi netti da servizi che sono aumentati a 587,7 milioni di dollari, rispetto ai 556,2 milioni di dollari del 2023. L'utile netto è stato di 16,9 milioni di dollari (0,51 dollari per azione diluita), rispetto ai 26,0 milioni di dollari (0,79 dollari per azione) del 2023, compresi i costi legati alla fusione di 16,7 milioni di dollari. Nel periodo di nove mesi, il fatturato è cresciuto a 1.750,3 milioni di dollari rispetto a 1.665,6 milioni di dollari, con un utile netto di 63,6 milioni di dollari rispetto a una perdita netta di 29,1 milioni di dollari nel 2023. L'EBITDA rettificato per il terzo trimestre del 2024 è stato di 58,1 milioni di dollari, leggermente superiore ai 57,9 milioni di dollari del 2023.
Amedisys (NASDAQ: AMED) informó sus resultados financieros del tercer trimestre de 2024, con ingresos netos por servicios que aumentaron a 587,7 millones de dólares, en comparación con 556,2 millones de dólares en 2023. La ganancia neta fue de 16,9 millones de dólares (0,51 dólares por acción diluida), frente a 26,0 millones de dólares (0,79 dólares por acción) en 2023, incluyendo gastos relacionados con fusiones por 16,7 millones de dólares. Durante el periodo de nueve meses, los ingresos crecieron a 1.750,3 millones de dólares desde 1.665,6 millones de dólares, con una ganancia neta de 63,6 millones de dólares en comparación con una pérdida neta de 29,1 millones de dólares en 2023. El EBITDA ajustado para el tercer trimestre de 2024 fue de 58,1 millones de dólares, ligeramente por encima de los 57,9 millones de dólares en 2023.
Amedisys (NASDAQ: AMED)는 2024년 3분기 재무 결과를 발표했습니다. 서비스 순수익이 5억 8,770만 달러로 증가했으며, 이는 2023년의 5억 5,620만 달러에서 상승한 수치입니다. 순이익은 1,690만 달러 (희석주당 0.51 달러)로, 2023년의 2,600만 달러 (주당 0.79 달러)에 비해 감소했으며, 합병 관련 비용이 1,670만 달러 포함되어 있습니다. 9개월 간의 기간 동안 수익은 17억 5,030만 달러로 증가했으며, 2023년의 2,910만 달러 순손실과 대조적으로 6,360만 달러의 순이익을 기록했습니다. 2024년 3분기 조정된 EBITDA는 5,810만 달러로, 2023년의 5,790만 달러에서 약간 증가했습니다.
Amedisys (NASDAQ: AMED) a publié ses résultats financiers pour le troisième trimestre 2024, avec un chiffre d'affaires net de services passant à 587,7 millions de dollars, contre 556,2 millions de dollars en 2023. Le revenu net s'est élevé à 16,9 millions de dollars (0,51 dollar par action diluée), comparé à 26,0 millions de dollars (0,79 dollar par action) en 2023, incluant des frais liés à la fusion de 16,7 millions de dollars. Pour la période de neuf mois, les revenus ont augmenté à 1.750,3 millions de dollars contre 1.665,6 millions de dollars, avec un revenu net de 63,6 millions de dollars par rapport à une perte nette de 29,1 millions de dollars en 2023. L'EBITDA ajusté pour le troisième trimestre 2024 était de 58,1 millions de dollars, légèrement supérieur aux 57,9 millions de dollars de 2023.
Amedisys (NASDAQ: AMED) hat die Finanzzahlen für das 3. Quartal 2024 bekannt gegeben, wobei der Nettodienstleistungsumsatz auf 587,7 Millionen Dollar gestiegen ist, verglichen mit 556,2 Millionen Dollar im Jahr 2023. Der Nettogewinn betrug 16,9 Millionen Dollar (0,51 Dollar pro verwässerter Aktie), im Vergleich zu 26,0 Millionen Dollar (0,79 Dollar pro Aktie) im Jahr 2023, einschließlich fusionsbedingter Kosten in Höhe von 16,7 Millionen Dollar. Für den Neunmonatszeitraum stieg der Umsatz auf 1.750,3 Millionen Dollar von 1.665,6 Millionen Dollar, mit einem Nettogewinn von 63,6 Millionen Dollar im Vergleich zu einem Nettverlust von 29,1 Millionen Dollar im Jahr 2023. Das bereinigte EBITDA für das 3. Quartal 2024 lag bei 58,1 Millionen Dollar und damit leicht über den 57,9 Millionen Dollar im Jahr 2023.
- Net service revenue increased by $31.5 million (5.7%) in Q3 2024
- Nine-month revenue grew by $84.7 million (5.1%) to $1,750.3 million
- Turned $29.1 million net loss to $63.6 million net income in nine-month period
- Slight improvement in adjusted EBITDA to $58.1 million
- Q3 net income decreased 35% to $16.9 million from $26.0 million
- Merger-related expenses increased to $16.7 million from $5.0 million
- Diluted EPS declined 35.4% to $0.51 from $0.79 in Q3
- Adjusted EPS remained nearly flat at $3.35 vs $3.36 for nine-month period
Insights
The Q3 2024 results show mixed performance with some concerning trends. While
The pending UnitedHealth Group merger is impacting financial performance through substantial related expenses (
BATON ROUGE, La., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three and nine-month periods ended September 30, 2024.
Three-Month Periods Ended September 30, 2024 and 2023
- Net service revenue increased
$31.5 million to$587.7 million compared to$556.2 million in 2023. - Net income attributable to Amedisys, Inc. of
$16.9 million , which is inclusive of merger-related expenses totaling$16.7 million ($16.7 million , net of tax) compared to net income attributable to Amedisys, Inc. of$26.0 million , which is inclusive of merger-related expenses totaling$5.0 million ($4.7 million , net of tax) in 2023. - Net income attributable to Amedisys, Inc. per diluted share of
$0.51 compared to$0.79 in 2023.
Adjusted Quarterly Results*
- Adjusted EBITDA of
$58.1 million compared to$57.9 million in 2023. - Adjusted net income attributable to Amedisys, Inc. of
$33.2 million compared to$32.2 million in 2023. - Adjusted net income attributable to Amedisys, Inc. per diluted share of
$1.00 compared to$0.98 in 2023.
Nine-Month Periods Ended September 30, 2024 and 2023
- Net service revenue increased
$84.7 million to$1,750.3 million compared to$1,665.6 million in 2023. - Net income attributable to Amedisys, Inc. of
$63.6 million , which is inclusive of merger-related expenses totaling$49.2 million ($48.0 million , net of tax) compared to net loss attributable to Amedisys, Inc. of$29.1 million , which is inclusive of merger-related expenses totaling$131.2 million ($130.9 million , net of tax) in 2023. - Net income attributable to Amedisys, Inc. per diluted share of
$1.93 compared to net loss attributable to Amedisys, Inc. per diluted share of$0.89 in 2023.
Adjusted Year to Date Results*
- Adjusted EBITDA of
$191.1 million compared to$190.4 million in 2023. - Adjusted net income attributable to Amedisys, Inc. of
$110.7 million compared to$109.8 million in 2023. - Adjusted net income attributable to Amedisys, Inc. per diluted share of
$3.35 compared to$3.36 in 2023.
* See pages 2 and 13 - 14 for the definition and reconciliations of non-GAAP financial measures to GAAP measures.
The supplemental slides provided in connection with the third quarter 2024 earnings release can be found on the Investor Relations page of our website. In light of the pending merger of the Company with UnitedHealth Group Incorporated, Amedisys will not conduct a quarterly earnings call to discuss the third quarter results.
Non-GAAP Financial Measures
This press release includes reconciliations of the most comparable financial measures calculated and presented in accordance with accounting principles generally accepted in the U.S. (“GAAP”) to non-GAAP financial measures. The non-GAAP financial measures as defined under SEC rules are as follows: (1) adjusted EBITDA, defined as net income (loss) attributable to Amedisys, Inc. before net interest expense, provision for income taxes and depreciation and amortization, excluding certain items; (2) adjusted net income attributable to Amedisys, Inc., defined as net income (loss) attributable to Amedisys, Inc. calculated in accordance with GAAP excluding certain items; and (3) adjusted net income attributable to Amedisys, Inc. per diluted share, defined as net income (loss) attributable to Amedisys, Inc. common stockholders per diluted share calculated in accordance with GAAP excluding certain items. Management believes that these non-GAAP financial measures, when reviewed in conjunction with GAAP financial measures, are useful gauges of our current performance and are also included in internal management reporting. These non-GAAP financial measures should be considered in addition to, and not more meaningful than or as an alternative to, the GAAP financial measures presented in this earnings release and the company’s financial statements. Non-GAAP measures as presented herein may not be comparable to similarly titled measures reported by other companies since not all companies calculate these non-GAAP measures consistently.
Additional Information
Amedisys, Inc. (the “Company”) is a leading healthcare at home company delivering personalized home health, hospice and high acuity care services. Amedisys is focused on delivering the care that is best for our patients, whether that is in-patient hospital, palliative and skilled nursing facility ("SNF") care in their homes, home-based recovery and rehabilitation after an operation or injury, care focused on empowering our patients to manage a chronic disease or hospice care at the end of life. More than 3,000 hospitals and 110,000 physicians nationwide have chosen Amedisys as a partner in post-acute care. Founded in 1982, headquartered in Baton Rouge, LA with an executive office in Nashville, TN, Amedisys is a publicly held company. With approximately 19,000 employees in 519 care centers within 37 states and the District of Columbia, Amedisys is dedicated to delivering the highest quality of care to the doorsteps of more than 469,000 patients every year. For more information about the Company, please visit: www.amedisys.com.
We use our website as a channel of distribution for important company information. Important information, including press releases, investor presentations and financial information regarding our company, is routinely posted on and accessible on the Investor Relations subpage of our website, which is accessible by clicking on the tab labeled “Investors” on our website home page. Visitors to our website can also register to receive automatic e-mail and other notifications alerting them when new information is made available on the Investor Relations subpage of our website.
Forward-Looking Statements
When included in this press release, words like “believes,” “belief,” “expects,” “strategy,” “plans,” “anticipates,” “intends,” “projects,” “estimates,” “may,” “might,” “will,” “could,” “would,” “should” and similar expressions are intended to identify forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a variety of risks and uncertainties that could cause actual results to differ materially from those described therein. These risks and uncertainties include, but are not limited to, the following: disruption from the proposed merger with UnitedHealth Group with patient, payor, provider, referral source, supplier or management and employee relationships; the occurrence of any event, change or other circumstances that could give rise to the termination of the merger agreement with UnitedHealth Group or the inability to complete the proposed transaction on the anticipated terms and timetable; the risk that necessary regulatory approvals for the proposed merger with UnitedHealth Group are delayed, are not obtained or are obtained subject to conditions that are not anticipated; the failure of the conditions to the proposed merger to be satisfied; the costs related to the proposed merger; the diversion of management time on merger-related issues; the risk that termination fees may be payable by the Company in the event that the merger agreement is terminated under certain circumstances; reputational risk related to the proposed merger; the risk of litigation or regulatory action related to the proposed merger; changes in Medicare and other medical payment levels; changes in payments and covered services by federal and state governments; future cost containment initiatives undertaken by third-party payors; changes in the episodic versus non-episodic mix of our payors, the case mix of our patients and payment methodologies; staffing shortages driven by the competitive labor market; our ability to attract and retain qualified personnel; competition in the healthcare industry; our ability to maintain or establish new patient referral sources; changes in or our failure to comply with existing federal and state laws or regulations or the inability to comply with new government regulations on a timely basis; changes in estimates and judgments associated with critical accounting policies; our ability to consistently provide high-quality care; our ability to keep our patients and employees safe; our access to financing; our ability to meet debt service requirements and comply with covenants in debt agreements; business disruptions due to natural or man-made disasters, climate change or acts of terrorism, widespread protests or civil unrest; our ability to open care centers, acquire additional care centers and integrate and operate these care centers effectively; our ability to realize the anticipated benefits of acquisitions, investments and joint ventures; our ability to integrate, manage and keep our information systems secure; the impact of inflation; and changes in laws or developments with respect to any litigation relating to the Company, including various other matters, many of which are beyond our control.
Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on any forward-looking statement as a prediction of future events. We expressly disclaim any obligation or undertaking and we do not intend to release publicly any updates or changes in our expectations concerning the forward-looking statements or any changes in events, conditions or circumstances upon which any forward-looking statement may be based, except as required by law.
| Contact: | Investor Contact: Amedisys, Inc. Nick Muscato Chief Strategy Officer (615) 928- 5452 IR@amedisys.com | Media Contact: Amedisys, Inc. Kendra Kimmons Vice President, Marketing & Communications (225) 299-3720 kendra.kimmons@amedisys.com |
| AMEDISYS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Amounts in thousands, except per share data) (Unaudited) | |||||||||||||||
| For the Three-Month Periods Ended September 30, | For the Nine-Month Periods Ended September 30, | ||||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||||
| Net service revenue | $ | 587,671 | $ | 556,237 | $ | 1,750,272 | $ | 1,665,594 | |||||||
| Operating expenses: | |||||||||||||||
| Cost of service, inclusive of depreciation | 337,563 | 311,628 | 986,033 | 924,093 | |||||||||||
| General and administrative expenses: | |||||||||||||||
| Salaries and benefits | 134,833 | 129,083 | 392,102 | 380,926 | |||||||||||
| Non-cash compensation | 6,726 | 6,612 | 21,987 | 18,968 | |||||||||||
| Merger-related expenses | 16,669 | 4,980 | 49,237 | 25,151 | |||||||||||
| Depreciation and amortization | 4,774 | 4,436 | 13,431 | 13,604 | |||||||||||
| Other | 56,777 | 57,287 | 173,320 | 180,467 | |||||||||||
| Total operating expenses | 557,342 | 514,026 | 1,636,110 | 1,543,209 | |||||||||||
| Operating income | 30,329 | 42,211 | 114,162 | 122,385 | |||||||||||
| Other income (expense): | |||||||||||||||
| Interest income | 2,017 | 1,304 | 5,361 | 2,452 | |||||||||||
| Interest expense | (7,772 | ) | (8,021 | ) | (23,786 | ) | (23,040 | ) | |||||||
| Equity in earnings from equity method investments | 1,891 | 1,252 | 4,316 | 9,366 | |||||||||||
| Merger termination fee | — | — | — | (106,000 | ) | ||||||||||
| Miscellaneous, net | 2,522 | 1,201 | 5,391 | 5,262 | |||||||||||
| Total other expense, net | (1,342 | ) | (4,264 | ) | (8,718 | ) | (111,960 | ) | |||||||
| Income before income taxes | 28,987 | 37,947 | 105,444 | 10,425 | |||||||||||
| Income tax expense | (12,473 | ) | (12,331 | ) | (41,763 | ) | (40,381 | ) | |||||||
| Net income (loss) | 16,514 | 25,616 | 63,681 | (29,956 | ) | ||||||||||
| Net (income) loss attributable to noncontrolling interests | 397 | 344 | (69 | ) | 887 | ||||||||||
| Net income (loss) attributable to Amedisys, Inc. | $ | 16,911 | $ | 25,960 | $ | 63,612 | $ | (29,069 | ) | ||||||
| Basic earnings per common share: | |||||||||||||||
| Net income (loss) attributable to Amedisys, Inc. common stockholders | $ | 0.52 | $ | 0.80 | $ | 1.94 | $ | (0.89 | ) | ||||||
| Weighted average shares outstanding | 32,745 | 32,624 | 32,707 | 32,587 | |||||||||||
| Diluted earnings per common share: | |||||||||||||||
| Net income (loss) attributable to Amedisys, Inc. common stockholders | $ | 0.51 | $ | 0.79 | $ | 1.93 | $ | (0.89 | ) | ||||||
| Weighted average shares outstanding | 33,135 | 32,831 | 33,020 | 32,587 | |||||||||||
| AMEDISYS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (Amounts in thousands, except share data) | |||||||
| September 30, 2024 (unaudited) | December 31, 2023 | ||||||
| ASSETS | |||||||
| Current assets: | |||||||
| Cash and cash equivalents | $ | 245,450 | $ | 126,450 | |||
| Restricted cash | — | 12,413 | |||||
| Patient accounts receivable | 301,050 | 313,373 | |||||
| Prepaid expenses | 20,485 | 14,639 | |||||
| Other current assets | 12,962 | 30,060 | |||||
| Total current assets | 579,947 | 496,935 | |||||
| Property and equipment, net of accumulated depreciation of | 42,000 | 41,845 | |||||
| Operating lease right of use assets | 85,110 | 88,939 | |||||
| Goodwill | 1,244,679 | 1,244,679 | |||||
| Intangible assets, net of accumulated amortization of | 99,698 | 102,675 | |||||
| Other assets | 87,680 | 85,097 | |||||
| Total assets | $ | 2,139,114 | $ | 2,060,170 | |||
| LIABILITIES AND EQUITY | |||||||
| Current liabilities: | |||||||
| Accounts payable | $ | 32,117 | $ | 28,237 | |||
| Payroll and employee benefits | 138,374 | 136,835 | |||||
| Accrued expenses | 145,611 | 140,049 | |||||
| Termination fee paid by UnitedHealth Group | 106,000 | 106,000 | |||||
| Current portion of long-term obligations | 37,478 | 36,314 | |||||
| Current portion of operating lease liabilities | 26,441 | 26,286 | |||||
| Total current liabilities | 486,021 | 473,721 | |||||
| Long-term obligations, less current portion | 344,428 | 361,862 | |||||
| Operating lease liabilities, less current portion | 59,323 | 62,751 | |||||
| Deferred income tax liabilities | 48,017 | 40,635 | |||||
| Other long-term obligations | 886 | 1,418 | |||||
| Total liabilities | 938,675 | 940,387 | |||||
| Equity: | |||||||
| Preferred stock, | — | — | |||||
| Common stock, | 38 | 38 | |||||
| Additional paid-in capital | 809,655 | 787,177 | |||||
| Treasury stock, at cost, 5,516,002 and 5,463,847 shares of common stock | (473,466 | ) | (468,626 | ) | |||
| Retained earnings | 811,537 | 747,925 | |||||
| Total Amedisys, Inc. stockholders’ equity | 1,147,764 | 1,066,514 | |||||
| Noncontrolling interests | 52,675 | 53,269 | |||||
| Total equity | 1,200,439 | 1,119,783 | |||||
| Total liabilities and equity | $ | 2,139,114 | $ | 2,060,170 | |||
AMEDISYS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS AND DAYS REVENUE OUTSTANDING (Amounts in thousands, except statistical information) (Unaudited) | |||||||||||||||
| For the Three-Month Periods Ended September 30, | For the Nine-Month Periods Ended September 30, | ||||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||||
| Cash Flows from Operating Activities: | |||||||||||||||
| Net income (loss) | $ | 16,514 | $ | 25,616 | $ | 63,681 | $ | (29,956 | ) | ||||||
| Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: | |||||||||||||||
| Depreciation and amortization (inclusive of depreciation included in cost of service) | 6,835 | 6,063 | 19,331 | 17,956 | |||||||||||
| Non-cash compensation | 6,206 | 7,243 | 22,390 | 19,624 | |||||||||||
| Amortization and impairment of operating lease right of use assets | 8,620 | 8,456 | 25,720 | 25,427 | |||||||||||
| (Gain) loss on disposal of property and equipment | (3 | ) | (10 | ) | (22 | ) | 346 | ||||||||
| Loss on personal care divestiture | — | — | — | 2,186 | |||||||||||
| Merger termination fee | — | — | — | 106,000 | |||||||||||
| Deferred income taxes | 805 | 7,313 | 7,382 | 15,417 | |||||||||||
| Equity in earnings from equity method investments | (1,891 | ) | (1,252 | ) | (4,316 | ) | (9,366 | ) | |||||||
| Amortization of deferred debt issuance costs | 248 | 248 | 743 | 743 | |||||||||||
| Return on equity method investments | 1,442 | 1,556 | 2,160 | 4,309 | |||||||||||
| Changes in operating assets and liabilities, net of impact of acquisitions: | |||||||||||||||
| Patient accounts receivable | 55,860 | (40,796 | ) | 11,503 | (32,934 | ) | |||||||||
| Other current assets | 8,115 | (17,123 | ) | 11,242 | (15,434 | ) | |||||||||
| Operating lease right of use assets | (1,066 | ) | (866 | ) | (3,135 | ) | (2,803 | ) | |||||||
| Other assets | 228 | 29 | 598 | 273 | |||||||||||
| Accounts payable | 5,860 | (4,108 | ) | 4,167 | (8,839 | ) | |||||||||
| Accrued expenses | 5,400 | 5,565 | 12,495 | 10,340 | |||||||||||
| Other long-term obligations | 41 | 23 | (532 | ) | (3,156 | ) | |||||||||
| Operating lease liabilities | (7,590 | ) | (7,800 | ) | (22,019 | ) | (23,256 | ) | |||||||
| Net cash provided by (used in) operating activities | 105,624 | (9,843 | ) | 151,388 | 76,877 | ||||||||||
| Cash Flows from Investing Activities: | |||||||||||||||
| Proceeds from the sale of deferred compensation plan assets | — | — | 21 | 25 | |||||||||||
| Proceeds from the sale of property and equipment | — | — | — | 100 | |||||||||||
| Purchases of property and equipment | (1,385 | ) | (984 | ) | (5,440 | ) | (3,728 | ) | |||||||
| Investments in technology assets | (210 | ) | (214 | ) | (619 | ) | (6,881 | ) | |||||||
| Investments in equity method investees | (850 | ) | — | (1,046 | ) | — | |||||||||
| Return of investment | — | 150 | — | 150 | |||||||||||
| Proceeds from personal care divestiture | — | — | — | 47,787 | |||||||||||
| Acquisitions of businesses, net of cash acquired | — | — | — | (350 | ) | ||||||||||
| Net cash (used in) provided by investing activities | (2,445 | ) | (1,048 | ) | (7,084 | ) | 37,103 | ||||||||
| Cash Flows from Financing Activities: | |||||||||||||||
| Proceeds from issuance of stock upon exercise of stock options | 88 | 25 | 88 | 100 | |||||||||||
| Proceeds from issuance of stock under employee stock purchase plan | — | 848 | — | 2,602 | |||||||||||
| Shares withheld to pay taxes on non-cash compensation | (645 | ) | (925 | ) | (4,840 | ) | (4,413 | ) | |||||||
| Noncontrolling interest contributions | — | 856 | 1,911 | 1,232 | |||||||||||
| Noncontrolling interest distributions | (610 | ) | (902 | ) | (2,574 | ) | (1,614 | ) | |||||||
| Purchase of noncontrolling interest | — | — | — | (800 | ) | ||||||||||
| Proceeds from borrowings under revolving line of credit | — | — | — | 23,000 | |||||||||||
| Repayments of borrowings under revolving line of credit | — | — | — | (23,000 | ) | ||||||||||
| Principal payments of long-term obligations | (9,348 | ) | (6,120 | ) | (27,730 | ) | (67,113 | ) | |||||||
| Payment of accrued contingent consideration | (4,572 | ) | (36 | ) | (4,572 | ) | (4,091 | ) | |||||||
| Net cash used in financing activities | (15,087 | ) | (6,254 | ) | (37,717 | ) | (74,097 | ) | |||||||
| Net increase (decrease) in cash, cash equivalents and restricted cash | 88,092 | (17,145 | ) | 106,587 | 39,883 | ||||||||||
| Cash, cash equivalents and restricted cash at beginning of period | 157,358 | 111,161 | 138,863 | 54,133 | |||||||||||
| Cash, cash equivalents and restricted cash at end of period | $ | 245,450 | $ | 94,016 | $ | 245,450 | $ | 94,016 | |||||||
| For the Three-Month Periods Ended September 30, | For the Nine-Month Periods Ended September 30, | ||||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||||
| Supplemental Disclosures of Cash Flow Information: | |||||||||||||||
| Cash paid for interest | $ | 7,313 | $ | 6,756 | $ | 23,220 | $ | 19,787 | |||||||
| Cash paid for income taxes, net of refunds received | $ | 9,600 | $ | 8,498 | $ | 27,993 | $ | 24,318 | |||||||
| Cash paid for operating lease liabilities | $ | 8,656 | $ | 8,665 | $ | 25,154 | $ | 26,059 | |||||||
| Cash paid for finance lease liabilities | $ | 3,723 | $ | 3,141 | $ | 10,834 | $ | 8,462 | |||||||
| Supplemental Disclosures of Non-Cash Activity: | |||||||||||||||
| Right of use assets obtained in exchange for operating lease liabilities | $ | 8,003 | $ | 10,459 | $ | 18,950 | $ | 25,261 | |||||||
| Right of use assets obtained in exchange for finance lease liabilities | $ | 2,211 | $ | 7,020 | $ | 12,228 | $ | 34,964 | |||||||
| Reductions to right of use assets resulting from reductions to operating lease liabilities | $ | 32 | $ | — | $ | 200 | $ | 15,135 | |||||||
| Reductions to right of use assets resulting from reductions to finance lease liabilities | $ | 393 | $ | 315 | $ | 1,512 | $ | 1,209 | |||||||
| Days revenue outstanding (1) | 44.4 | 49.8 | 44.4 | 49.8 | |||||||||||
(1) Our calculation of days revenue outstanding at September 30, 2024 and 2023 is derived by dividing our ending patient accounts receivable by our average daily patient revenue for the three-month periods ended September 30, 2024 and 2023, respectively.
| AMEDISYS, INC. AND SUBSIDIARIES SEGMENT INFORMATION (Amounts in millions, except statistical information) (Unaudited) | |||||||
| Segment Information - Home Health | |||||||
| For the Three-Month Periods Ended September 30, | |||||||
| 2024 | 2023 | ||||||
| Financial Information(in millions): | |||||||
| Medicare | $ | 212.1 | $ | 217.9 | |||
| Non-Medicare | 160.0 | 133.7 | |||||
| Net service revenue | 372.1 | 351.6 | |||||
| Cost of service, inclusive of depreciation | 222.2 | 201.6 | |||||
| Gross margin | 149.9 | 150.0 | |||||
| General and administrative expenses | 93.3 | 91.4 | |||||
| Depreciation and amortization | 2.1 | 1.8 | |||||
| Operating income | $ | 54.5 | $ | 56.8 | |||
| Same Store Growth(1): | |||||||
| Medicare revenue | (3 | %) | (2 | %) | |||
| Non-Medicare revenue | 20 | % | 17 | % | |||
| Total admissions | 12 | % | 4 | % | |||
| Total volume(2) | 9 | % | 3 | % | |||
| Key Statistical Data - Total(3): | |||||||
| Admissions | 109,856 | 98,527 | |||||
| Recertifications | 47,431 | 45,693 | |||||
| Total volume | 157,287 | 144,220 | |||||
| Medicare completed episodes | 71,118 | 72,714 | |||||
| Average Medicare revenue per completed episode(4) | $ | 3,021 | $ | 3,015 | |||
| Medicare visits per completed episode(5) | 12.0 | 12.4 | |||||
| Visiting clinician cost per visit | $ | 108.87 | $ | 105.06 | |||
| Clinical manager cost per visit | 12.65 | 11.98 | |||||
| Total cost per visit | $ | 121.52 | $ | 117.04 | |||
| Visits | 1,829,075 | 1,723,289 | |||||
| For the Nine-Month Periods Ended September 30, | |||||||
| 2024 | 2023 | ||||||
| Financial Information(in millions): | |||||||
| Medicare | $ | 644.0 | $ | 653.1 | |||
| Non-Medicare | 469.5 | 391.6 | |||||
| Net service revenue | 1,113.5 | 1,044.7 | |||||
| Cost of service, inclusive of depreciation | 648.6 | 593.1 | |||||
| Gross margin | 464.9 | 451.6 | |||||
| General and administrative expenses | 276.8 | 270.5 | |||||
| Depreciation and amortization | 5.7 | 4.3 | |||||
| Operating income | $ | 182.4 | $ | 176.8 | |||
| Same Store Growth(1): | |||||||
| Medicare revenue | (1 | %) | (3 | %) | |||
| Non-Medicare revenue | 20 | % | 13 | % | |||
| Total admissions | 12 | % | 5 | % | |||
| Total volume(2) | 9 | % | 3 | % | |||
| Key Statistical Data - Total(3): | |||||||
| Admissions | 332,259 | 297,943 | |||||
| Recertifications | 137,562 | 134,826 | |||||
| Total volume | 469,821 | 432,769 | |||||
| Medicare completed episodes | 217,116 | 221,125 | |||||
| Average Medicare revenue per completed episode(4) | $ | 3,018 | $ | 2,998 | |||
| Medicare visits per completed episode(5) | 12.0 | 12.4 | |||||
| Visiting clinician cost per visit | $ | 106.76 | $ | 101.55 | |||
| Clinical manager cost per visit | 12.18 | 11.41 | |||||
| Total cost per visit | $ | 118.94 | $ | 112.96 | |||
| Visits | 5,453,694 | 5,250,944 | |||||
(1) Same store information represents the percent change in our Medicare, Non-Medicare and Total revenue, admissions or volume for the period as a percent of the Medicare, Non-Medicare and Total revenue, admissions or volume of the prior period. Same store is defined as care centers that we have operated for at least the last twelve months and startups that are an expansion of a same store care center.
(2) Total volume includes all admissions and recertifications.
(3) Total includes acquisitions, start-ups and de novos.
(4) Average Medicare revenue per completed episode is the average Medicare revenue earned for each Medicare completed episode of care.
(5) Medicare visits per completed episode are the home health Medicare visits on completed episodes divided by the home health Medicare episodes completed during the period.
| Segment Information - Hospice | |||||||
| For the Three-Month Periods Ended September 30, | |||||||
| 2024 | 2023 | ||||||
| Financial Information(in millions): | |||||||
| Medicare | $ | 197.8 | $ | 188.9 | |||
| Non-Medicare | 10.1 | 11.3 | |||||
| Net service revenue | 207.9 | 200.2 | |||||
| Cost of service, inclusive of depreciation | 107.7 | 104.2 | |||||
| Gross margin | 100.2 | 96.0 | |||||
| General and administrative expenses | 49.7 | 48.4 | |||||
| Depreciation and amortization | 0.8 | 0.8 | |||||
| Operating income | $ | 49.7 | $ | 46.8 | |||
| Same Store Growth(1): | |||||||
| Medicare revenue | 5 | % | 1 | % | |||
| Hospice admissions | (4 | %) | (6 | %) | |||
| Average daily census | 1 | % | (2 | %) | |||
| Key Statistical Data - Total(2): | |||||||
| Hospice admissions | 11,488 | 11,968 | |||||
| Average daily census | 13,004 | 12,943 | |||||
| Revenue per day, net | $ | 173.74 | $ | 168.11 | |||
| Cost of service per day | $ | 89.92 | $ | 87.48 | |||
| Average discharge length of stay | 98 | 94 | |||||
| For the None-Month Periods Ended September 30, | |||||||
| 2024 | 2023 | ||||||
| Financial Information(in millions): | |||||||
| Medicare | $ | 581.5 | $ | 559.8 | |||
| Non-Medicare | 31.4 | 33.0 | |||||
| Net service revenue | 612.9 | 592.8 | |||||
| Cost of service, inclusive of depreciation | 317.6 | 304.4 | |||||
| Gross margin | 295.3 | 288.4 | |||||
| General and administrative expenses | 146.5 | 144.1 | |||||
| Depreciation and amortization | 2.3 | 2.2 | |||||
| Operating income | $ | 146.5 | $ | 142.1 | |||
| Same Store Growth(1): | |||||||
| Medicare revenue | 4 | % | — | % | |||
| Hospice admissions | (3 | %) | (6 | %) | |||
| Average daily census | — | % | (2 | %) | |||
| Key Statistical Data - Total(2): | |||||||
| Hospice admissions | 36,269 | 37,361 | |||||
| Average daily census | 12,913 | 12,864 | |||||
| Revenue per day, net | $ | 173.22 | $ | 168.80 | |||
| Cost of service per day | $ | 89.73 | $ | 86.66 | |||
| Average discharge length of stay | 93 | 91 | |||||
(1) Same store information represents the percent change in our Medicare revenue, Hospice admissions or average daily census for the period as a percent of the Medicare revenue, Hospice admissions or average daily census of the prior period. Same store is defined as care centers that we have operated for at least the last twelve months and startups that are an expansion of a same store care center.
(2) Total includes acquisitions and de novos.
| Segment Information - Personal Care(1) | |||||
| For the Nine-Month Periods Ended September 30, | |||||
| 2024 | 2023 | ||||
| Financial Information(in millions): | |||||
| Medicare | $ | — | $ | — | |
| Non-Medicare | — | 15.0 | |||
| Net service revenue | — | 15.0 | |||
| Cost of service, inclusive of depreciation | — | 11.1 | |||
| Gross margin | — | 3.9 | |||
| General and administrative expenses | — | 2.3 | |||
| Depreciation and amortization | — | — | |||
| Operating income | $ | — | $ | 1.6 | |
| Key Statistical Data - Total: | |||||
| Billable hours | — | 440,464 | |||
| Clients served | — | 7,892 | |||
| Shifts | — | 191,379 | |||
| Revenue per hour | $ | — | $ | 33.97 | |
| Revenue per shift | $ | — | $ | 78.19 | |
| Hours per shift | — | 2.3 | |||
(1) We completed the sale of our personal care business on March 31, 2023.
| Segment Information - High Acuity Care | |||||||
| For the Three-Month Periods Ended September 30, | |||||||
| 2024 | 2023 | ||||||
| Financial Information(in millions): | |||||||
| Medicare | $ | — | $ | — | |||
| Non-Medicare | 7.7 | 4.4 | |||||
| Net service revenue | 7.7 | 4.4 | |||||
| Cost of service, inclusive of depreciation | 7.7 | 5.8 | |||||
| Gross margin | — | (1.4 | ) | ||||
| General and administrative expenses | 5.7 | 5.3 | |||||
| Depreciation and amortization | 0.8 | 0.7 | |||||
| Operating loss | $ | (6.5 | ) | $ | (7.4 | ) | |
| Key Statistical Data - Total: | |||||||
| Full risk admissions | 217 | 150 | |||||
| Limited risk admissions | 656 | 430 | |||||
| Total admissions | 873 | 580 | |||||
| Total admissions growth | 51 | % | 35 | % | |||
| Full risk revenue per episode | $ | 9,997 | $ | 10,168 | |||
| Limited risk revenue per episode | $ | 6,623 | $ | 6,242 | |||
| Number of admitting joint ventures | 9 | 10 | |||||
| For the Nine-Month Periods Ended September 30, | |||||||
| 2024 | 2023 | ||||||
| Financial Information(in millions): | |||||||
| Medicare | $ | — | $ | — | |||
| Non-Medicare | 23.9 | 13.1 | |||||
| Net service revenue | 23.9 | 13.1 | |||||
| Cost of service, inclusive of depreciation | 19.9 | 15.5 | |||||
| Gross margin | 4.0 | (2.4 | ) | ||||
| General and administrative expenses | 17.0 | 15.0 | |||||
| Depreciation and amortization | 2.5 | 2.3 | |||||
| Operating loss | $ | (15.5 | ) | $ | (19.7 | ) | |
| Key Statistical Data - Total: | |||||||
| Full risk admissions | 513 | 468 | |||||
| Limited risk admissions | 1,953 | 1,263 | |||||
| Total admissions | 2,466 | 1,731 | |||||
| Total admissions growth | 42 | % | 56 | % | |||
| Full risk revenue per episode | $ | 10,056 | $ | 10,783 | |||
| Limited risk revenue per episode | $ | 6,740 | $ | 5,881 | |||
| Number of admitting joint ventures | 9 | 10 | |||||
| Segment Information - Corporate | |||||
| For the Three-Month Periods Ended September 30, | |||||
| 2024 | 2023 | ||||
| Financial Information(in millions): | |||||
| General and administrative expenses | $ | 66.3 | $ | 52.9 | |
| Depreciation and amortization | 1.1 | 1.1 | |||
| Total operating expenses | $ | 67.4 | $ | 54.0 | |
| For the Nine-Month Periods Ended September 30, | |||||
| 2024 | 2023 | ||||
| Financial Information(in millions): | |||||
| General and administrative expenses | $ | 196.3 | $ | 173.6 | |
| Depreciation and amortization | 2.9 | 4.8 | |||
| Total operating expenses | $ | 199.2 | $ | 178.4 | |
| AMEDISYS, INC. AND SUBSIDIARIES RECONCILIATION OF NON-GAAP FINANCIAL MEASURES TO GAAP MEASURES (Amounts in thousands) (Unaudited) | ||||||||||||
| Adjusted Earnings Before Interest, Taxes, Depreciation and Amortization ("Adjusted EBITDA") Reconciliation: | ||||||||||||
| For the Three-Month Periods Ended September 30, | For the Nine-Month Periods Ended September 30, | |||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||
| Net income (loss) attributable to Amedisys, Inc. | $ | 16,911 | $ | 25,960 | $ | 63,612 | $ | (29,069 | ) | |||
| Add: | ||||||||||||
| Income tax expense | 12,473 | 12,331 | 41,763 | 40,381 | ||||||||
| Interest expense, net | 5,755 | 6,717 | 18,425 | 20,588 | ||||||||
| Depreciation and amortization | 6,835 | 6,063 | 19,331 | 17,956 | ||||||||
| Certain items(1) | 16,131 | 6,807 | 47,993 | 140,498 | ||||||||
| Adjusted EBITDA(2)(5) | $ | 58,105 | $ | 57,878 | $ | 191,124 | $ | 190,354 | ||||
| Adjusted Net Income Attributable to Amedisys, Inc Reconciliation: | ||||||||||||
| For the Three-Month Periods Ended September 30, | For the Nine-Month Periods Ended September 30, | |||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||
| Net income (loss) attributable to Amedisys, Inc. | $ | 16,911 | $ | 25,960 | $ | 63,612 | $ | (29,069 | ) | |||
| Add: | ||||||||||||
| Certain items(1) | 16,333 | 6,242 | 47,122 | 138,884 | ||||||||
| Adjusted net income attributable to Amedisys, Inc.(3)(5) | $ | 33,244 | $ | 32,202 | $ | 110,734 | $ | 109,815 | ||||
| Adjusted Net Income Attributable to Amedisys, Inc. per Diluted Share Reconciliation: | ||||||||||||
| For the Three-Month Periods Ended September 30, | For the Nine-Month Periods Ended September 30, | |||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||
| Net income (loss) attributable to Amedisys, Inc. common stockholders per diluted share | $ | 0.51 | $ | 0.79 | $ | 1.93 | $ | (0.89 | ) | |||
| Add: | ||||||||||||
| Certain items(1) | 0.49 | 0.19 | 1.43 | 4.25 | ||||||||
| Adjusted net income attributable to Amedisys, Inc. common stockholders per diluted share(4)(5) | $ | 1.00 | $ | 0.98 | $ | 3.35 | $ | 3.36 | ||||
(1) The following details the certain items for the three and nine-month periods ended September 30, 2024 and 2023:
Certain Items (in thousands): | |||||||
| For the Three-Month Periods Ended September 30, 2024 | For the Nine-Month Periods Ended September 30, 2024 | ||||||
| (Income) Expense | (Income) Expense | ||||||
| Certain Items Impacting General and Administrative Expenses: | |||||||
| Merger-related expenses | $ | 16,669 | $ | 49,237 | |||
| Certain Items Impacting Total Other Income (Expense): | |||||||
| Other (income) expense, net | (538 | ) | (1,244 | ) | |||
| Total | $ | 16,131 | $ | 47,993 | |||
| Net of tax | $ | 16,333 | $ | 47,122 | |||
| Diluted EPS | $ | 0.49 | $ | 1.43 | |||
| For the Three-Month Periods Ended September 30, 2023 | For the Nine-Month Periods Ended September 30, 2023 | |||||
| (Income) Expense | (Income) Expense | |||||
| Certain Items Impacting Cost of Service, Inclusive of Depreciation: | ||||||
| Clinical optimization and reorganization costs | $ | 282 | 396 | |||
| Certain Items Impacting General and Administrative Expenses: | ||||||
| Acquisition and integration costs | 338 | 3,106 | ||||
| CEO transition | 1,094 | 5,279 | ||||
| Merger-related expenses | 4,980 | 25,151 | ||||
| Clinical optimization and reorganization costs | 466 | 4,203 | ||||
| Personal care divestiture | — | 525 | ||||
| Certain Items Impacting Total Other Income (Expense): | ||||||
| Other (income) expense, net (includes | (353 | ) | 101,838 | |||
| Total | $ | 6,807 | $ | 140,498 | ||
| Net of tax | $ | 6,242 | $ | 138,884 | ||
| Diluted EPS | $ | 0.19 | $ | 4.25 | ||
(2) Adjusted EBITDA is defined as net income (loss) attributable to Amedisys, Inc. before net interest expense, provision for income taxes and depreciation and amortization, excluding certain items as described in footnote 1.
(3) Adjusted net income attributable to Amedisys, Inc. is defined as net income (loss) attributable to Amedisys, Inc. calculated in accordance with GAAP excluding certain items as described in footnote 1.
(4) Adjusted net income attributable to Amedisys, Inc. common stockholders per diluted share is defined as diluted income (loss) per share calculated in accordance with GAAP excluding the earnings per share effect of certain items as described in footnote 1.
(5) Adjusted EBITDA, adjusted net income attributable to Amedisys, Inc. and adjusted net income attributable to Amedisys, Inc. common stockholders per diluted share should not be considered as an alternative to, or more meaningful than, income before income taxes or other measures calculated in accordance with GAAP. These calculations may not be comparable to a similarly titled measure reported by other companies, since not all companies calculate these non-GAAP financial measures in the same manner.
FAQ
What was Amedisys (AMED) revenue in Q3 2024?
How much did AMED earn per share in Q3 2024?
What was Amedisys (AMED) adjusted EBITDA for Q3 2024?
How much were AMED's merger-related expenses in Q3 2024?
